Revolution in Mental Health Treatment: Trump's Psychedelic Drug Order
President Donald Trump signed an executive order to expedite access to psychedelic drugs for medical treatments. The U.S. FDA is focused on drugs like ibogaine for PTSD and depression, with $50 million allocated for research. Results could lead to drug reclassification after trials.
In a groundbreaking move, President Donald Trump has signed an executive order aimed at accelerating the access to medical research and treatments that employ psychedelic drugs.
The initiative directs the U.S. Food and Drug Administration (FDA) to expedite the review of drugs such as ibogaine. This development is particularly significant for military veterans who seek treatment for post-traumatic stress disorder (PTSD), a condition that these psychedelic substances potentially alleviate.
U.S. Health Secretary Robert F. Kennedy Jr., a vocal advocate for alternative treatments, supports this push. The government has announced a federal research budget of $50 million specifically for ibogaine investigations. FDA Commissioner Marty Makary indicated that decisions regarding these drugs could emerge as early as this summer.
(With inputs from agencies.)
- READ MORE ON:
- Trump
- executive order
- psychedelic drugs
- ibogaine
- PTSD
- FDA
- research
- mental health
- depression
- treatment
ALSO READ
Upheaval at the FDA: Leadership Changes Amid Controversy
Shake-Up at FDA: Tracy Beth Hoeg Expected to Leave Amid Vaccine Policy Controversy
Shake-Up at FDA: Uncertainty as Key Leader Departs
Recharging Brain's Engines: A New Frontier in Dementia Research
WHO Launches Free Global Online Course to Improve Clinical Trial Quality and Ethical Research Standards
Google News